WithdrawnNCT03852160
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Medication studyAges 18–74
Understand this study
Who could participate?
Listed age limits: 18 years to 74 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: December 1, 2019
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT03852160
- Official title
Show the full official title
A Randomized, Double-Blind, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly-dosed Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Recruitment & locations
WithdrawnLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Does this study involve medication?
Yes. The study involves medication, including Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo, Escitalopram, Sertraline, Duloxetine, Mirtazapine, Agomelatine, Bupropion and Trazodone Prolonged Release.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
